Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL126974 | 0.86 | HTT (0.66) | LMNASMN1; SMN2HTTALDH1A1CTSL | |
| SCHEMBL6741072 | 0.86 | LMNA (0.65) | LMNASMN1; SMN2HTTALDH1A1CTSL | |
| SCHEMBL11783251 | 0.86 | HTT (0.66) | LMNASMN1; SMN2HTTALDH1A1CTSL | |
| Hydrochloric Acid SCHEMBL8688569 | 0.84 | HTT (0.64) | LMNASMN1; SMN2HTTALDH1A1CTSL | |
| SCHEMBL10081124 | 0.84 | LMNA (0.63) | LMNASMN1; SMN2HTTALDH1A1CTSL | |
| SCHEMBL11143560 | 0.84 | LMNA (0.63) | LMNASMN1; SMN2HTTALDH1A1CTSL | |
| SCHEMBL250620 | 0.84 | LMNA (0.67) | LMNASMN1; SMN2HTTALDH1A1CTSL | |
| SCHEMBL4462583 | 0.83 | LMNA (0.61) | LMNASMN1; SMN2HTTALDH1A1CTSL | |
| SCHEMBL3361808 | 0.83 | LMNA (0.61) | LMNASMN1; SMN2HTTALDH1A1CTSL | |
| SCHEMBL7765686 | 0.83 | LMNA (0.61) | LMNASMN1; SMN2HTTALDH1A1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246810-B1 | PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS | ORTHO MCNEIL PHARM INC (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6518285-B2 | 4-oxo-5-oxazolidineylmethyl derivatives; antibacterials which are active against numerous multidrug-resistant gram positive organisms | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-02-11 | — | — | US | disclosed |
| EP-1246810-A1 | PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020103377-A1 | Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001046164-A1 | PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103377-A1 | Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials | OXA1L, RPS27L, RPS27 | LMNA 4373/4885SMN1; SMN2 3906/4885HTT 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.